Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against solid tumors and infectious diseases, announced today that the U.S. Patent and ...

Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome ...

“These early clinical results are exactly what we’ve been hoping for and demonstrate CHS-114’s ability to remodel the tumor microenvironment ... statements. Factors that may affect future ...

“The poster presents a significant upregulation of STAT3, IRS1/2 and b-catenin in HNSCC tumors and tumor microenvironment ... factors besides those we have listed could also adversely affect ...

Welcome to Vir Biotechnology's First Quarter 2025 Financial Results and Business Update Call ... activate T-cell engagers in the tumor microenvironment, potentially providing a wider therapeutic ...

MIAMI--(BUSINESS WIRE ... of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets ...

MIAMI--(BUSINESS WIRE ... of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets ...

Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...